Inflammatory events in endometrial adenocarcinoma

Journal of Endocrinology

Volumn 206, Issue 2, 2010, Pages 141-157

  Wallace, Alison E ^a   Gibson, Douglas A ^a   Saunders, Philippa T K ^a   Jabbour, Henry N ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTAGLANDIN; RANTES; ANDROGEN; CHEMOKINE; CYTOKINE; GLUCOCORTICOID; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PTEN PROTEIN, HUMAN; RAS PROTEIN;

CARCINOGENESIS; CELL INFILTRATION; CYTOKINE RELEASE; CYTOTOXICITY; DISEASE EXACERBATION; ENDOMETRIUM CARCINOMA; GENE MUTATION; HEREDITY; HORMONAL CARCINOGENESIS; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; LEUKOCYTE; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUATION; NULLIPARA; OBESITY; ONCOGENE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; DISEASE COURSE; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; UPREGULATION;

ADENOCARCINOMA; ANDROGENS; CHEMOKINES; CYTOKINES; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LEUKOCYTES; MENSTRUATION; MUTATION; NF-KAPPA B; PROGESTERONE; PROSTAGLANDINS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 77955061767     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-10-0072     Document Type: Review

References (200)

1. Ai S, Cheng XW, Inoue A, Nakamura K, Okumura K, Iguchi A, Murohara T & Kuzuya M 2007 Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. Biochemical and Biophysical Research Communications 364 395-401. (Pubitemid 350011074)
2. Akhmedkhanov A, Zeleniuch-Jacquotte A & Toniolo P 2001 Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Annals of the New York Academy of Sciences 943 296-315. (Pubitemid 32928322)
3. Akiyama M, Okabe H, Takakura K, Fujiyama Y & Noda Y 1999 Expression of macrophage inflammatory protein-1α (MIP-1α) in human endometrium throughout the menstrual cycle. British Journal of Obstetrics and Gynaecology 106 725-730. (Pubitemid 29304397)
4. Albrektsen G, Heuch I, Tretli S & Kvale G 1995 Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women International Journal of Cancer 61 485-490.
5. Alexander IE, Clarke CL, Shine J & Sutherland RL 1989 Progestin inhibition of progesterone receptor gene expression in human breast cancer cells. Molecular Endocrinology 3 1377-1386. (Pubitemid 19242065)
6. Apparao KB, Lovely LP, Gui Y, Lininger RA & Lessey BA 2002 Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biology of Reproduction 66 297-304. (Pubitemid 34103009)
7. Ardi VC, Kupriyanova TA, Deryugina EI & Quigley JP 2007 Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. PNAS 104 20262-20267.
8. Arici A, Seli E, Senturk LM, Gutierrez LS, Oral E & Taylor HS 1998 Interleukin-8 in the human endometrium. Journal of Clinical Endocrinology and Metabolism 83 1783-1787.
9. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH et al. 2006 Prognostic value of tumor-infiltrating CD4CT-cell subpopulations in head and neck cancers. Clinical Cancer Research 12 465-472.
10. Balkwill F & Mantovani A 2001 Inflammation and cancer: back to Virchow? Lancet 357 539-545.
11. Bamberger AM, Milde-Langosch K, Loning T & Bamberger CM 2001 The glucocorticoid receptor is specifically expressed in the stromal compartment of the human endometrium. Journal of Clinical Endocrinology and Metabolism 86 5071-5074. (Pubitemid 33020566)
12. Barrientos S, Stojadinovic O, Golinko MS, Brem H & Tomic-Canic M 2008 Growth factors and cytokines in wound healing. Wound Repair and Regeneration 16 585-601.
13. 2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Human Reproduction 22 36-44.
14. Beining RM, Dennis LK, Smith EM & Dokras A 2008 Meta-analysis of intrauterine device use and risk of endometrial cancer. Annals of Epidemiology 18 492-499.
15. Bellone S, Watts K, Cane S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S & Santin AD 2005 High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 98 92-98.
16. Beral V, Bull D & Reeves G 2005 Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 1543-1551. (Pubitemid 40615403)
17. Bergstrom A, Pisani P, Tenet V, Wolk A & Adami HO 2001 Overweight as an avoidable cause of cancer in Europe. International Journal of Cancer 91 421-430. (Pubitemid 32049639)
18. Berry KK, Varney ML, Dave BJ, Bucana CD, Fidler IJ & Singh RK 2001 Expression of interleukin-8 in human metastatic endometrial carcinoma cells and its regulation by inflammatory cytokines. International Journal of Gynecological Cancer 11 54-60. (Pubitemid 32216908)
19. Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, Turkevitch EA, Tsyrlina EV, Maximov SJ, Ashrafian LA et al. 2003 Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. Journal of Cancer Research and Clinical Oncology 129 245-249.
20. Bingle L, Lewis CE, Corke KP, Reed MW & Brown NJ 2006 Macrophages promote angiogenesis in human breast tumour spheroids in vivo. British Journal of Cancer 94 101-107. (Pubitemid 43088548)
21. Bokhman JV 1983 Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology 15 10-17.
22. Bonnotte B, Crittenden M, Larmonier N, Gough N & Vile RG 2004 MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. The Journal of Immunology 173 4929-4935. (Pubitemid 39387774)
23. Brosens JJ, Lam EW & Parker MG 2006 Inflammation and sex steroid receptors: a motif for change. Cell 124 466-468. (Pubitemid 43199432)
24. Bulun SE, Economos K, Miller D & Simpson ER 1994 CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. Journal of Clinical Endocrinology and Metabolism 79 1831-1834.
25. van der Burg B & van der Saag PT 1996 Nuclear factor-κB/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. Molecular Human Reproduction 2 433-438.
26. Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN & Colgan SP 2007 Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB Journal 21 3162-3170. (Pubitemid 47565535)
27. Catasus L, Gallardo A, Cuatrecasas M& Prat J 2009 Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Modern Pathology 22 522-529.
28. Chang WC, Huang SC, Torng PL, Chang DY, Hsu WC, Chiou SH, Chow SN & Sheu BC 2005 Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+T lymphocyte lineage in human endometrial carcinoma. International Journal of Gynecological Cancer 15 1073-1080.
29. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T & Mor G 2008 Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells. Oncogene 27 4712-4723.
30. Chittenden BG, Fullerton G, Maheshwari A & Bhattacharya S 2009 Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reproductive Biomedicine Online 19 398-405.
31. Choi DS, Kim HJ, Yoon JH, Yoo SC, Jo H, Lee SY, Min CK & Ryu HS 2009 Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-α and stromal derived hepatocyte growth factor. International Journal of Cancer 124 2528-2538.
32. Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN & Saunders PT 2009 Expression of oestrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERα. BMC Cancer 9 330.
33. Colotta F, Allavena P, Sica A, Garlanda C &Mantovani A 2009 Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 1073-1081.
34. Conti I & Rollins BJ 2004 CCL2 (monocyte chemoattractant protein-1) and cancer. Seminars in Cancer Biology 14 149-154. (Pubitemid 38586739)
35. Courtois G & Gilmore TD 2006 Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 25 6831-6843. (Pubitemid 44657855)
36. Couse JF & Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocrine Reviews 20 358-417.
37. Critchley HO & Saunders PT 2009 Hormone receptor dynamics in a receptive human endometrium. Reproductive Sciences 16 191-199.
38. Critchley HO, Kelly RW& Kooy J 1994 Perivascular location of a chemokine interleukin-8 in human endometrium: a preliminary report. Human Reproduction 9 1406-1409. (Pubitemid 24270025)
39. Critchley HO, Jones RL, Lea RG, Drudy TA, Kelly RW, Williams AR & Baird DT 1999 Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. Journal of Clinical Endocrinology and Metabolism 84 240-248.
40. Critchley HO, Kelly RW, Brenner RM & Baird DT 2001a The endocrinology of menstruation - a role for the immune system. Clinical Endocrinology 55 701-710. (Pubitemid 34008738)
41. Critchley HOD, Brenner RM, Henderson TA, Williams K, Nayak NR, Slayden OD, Millar MR & Saunders PTK 2001b Estrogen receptor β, but not estrogen receptor α, is present in the vascular endothelium of the human and nonhuman primate endometrium. Journal of Clinical Endocrinology and Metabolism 86 1370-1378.
42. Cullinan EB, Abbondanzo SJ, Anderson PS, Pollard JW, Lessey BA & Stewart CL 1996 Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation. PNAS 93 3115-3120.
43. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, Ellenson LH & Dey SK 2008 Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Research 68 5619-5627.
44. Danforth KN, Gierach GL, Brinton LA, Hollenbeck AR, Katki HA, Leitzmann MF, Schatzkin A & Lacey JV Jr 2009 Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prevention Research 2 466-472.
45. Dannenberg AJ & Subbaramaiah K 2003 Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 431-436.
46. Davies S, Dai D, Feldman I, Pickett G & Leslie KK 2004 Identification of a novel mechanism of NF-κB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. Gynecologic Oncology 94 463-470.
47. Dimitriadis E, Salamonsen LA & Robb L 2000 Expression of interleukin-11 during the human menstrual cycle: coincidence with stromal cell decidualization and relationship to leukaemia inhibitory factor and prolactin. Molecular Human Reproduction 6 907-914.
48. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colas E, Llaurado M, Alazzouzi H, Planaguma J et al. 2008 Novel molecular profiles of endometrial cancer - new light through old windows. Journal of Steroid Biochemistry and Molecular Biology 108 221-229.
49. Edwards JP, Zhang X & Mosser DM 2009 The expression of heparin-binding epidermal growth factor-like growth factor by regulatory macrophages. Journal of Immunology 182 1929-1939.
50. Ellenson LH & Wu TC 2004 Focus on endometrial and cervical cancer. Cancer Cell 5 533-538.
51. Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O & Rice JM 1990 K-ras activation in neoplasms of the human female reproductive tract. Cancer Research 50 6139-6145.
52. Fainaru O, Adini A, Benny O, Adini I, Short S, Bazinet L, Nakai K, Pravda E, Hornstein MD, D'Amato RJ et al. 2008 Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis. The FASEB Journal 22 522-529.
53. Ferenczy A, Bertrand G & Gelfand MM 1979 Proliferation kinetics of human endometrium during the normal menstrual cycle. American Journal of Obstetrics and Gynecology 133 859-867.
54. Finn CA 1986 Implantation, menstruation and inflammation. Biological Reviews of the Cambridge Philosophical Society 61 313-328.
55. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L & Gallion H 2004 Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin +24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group Study. Annals of Oncology 15 1173-1178.
56. Flossmann E & Rothwell PM 2007 Commentary: aspirin and colorectal cancer an epidemiological success story. International Journal of Epidemiology 36 962-965.
57. Fortuny J, Sima C, Bayuga S, Wilcox H, Pulick K, Faulkner S, Zauber AG & Olson SH 2009 Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiology, Biomarkers and Prevention 18 1448-1456.
58. Fujimoto J, Aoki I, Khatun S, Toyoki H & Tamaya T 2002 Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers. Annals of Oncology 13 430-434. (Pubitemid 34705005)
59. Fujino H & Regan JW 2003 Prostaglandin F(2α) stimulation of cyclooxygenase-2 promoter activity by the FP(B) prostanoid receptor. European Journal of Pharmacology 465 39-41.
60. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S & Carbone DP 1998 Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 4150-4166.
61. Gargett CE, Lederman F, Heryanto B, Gambino LS & Rogers PA 2001 Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils. Human Reproduction 16 1065-1075.
62. Gates EJ, Hirschfield L, Matthews RP & Yap OW 2006 Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. Journal of the National Medical Association 98 1814-1822. (Pubitemid 44885538)
63. Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL, Fambrini M, Taddei GL, Serio M & Orlando C 2009 The CXCR4/CXCL12 axis in endometrial cancer. Clinical and Experimental Metastasis 26 261-268.
64. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL & Banham AH 2008 The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecologic Oncology 110 216-221.
65. Giudice LC 2006 Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Practice & Research. Clinical Endocrinology and Metabolism 20 235-244.
66. Gori F, Hofbauer LC, Conover CA & Khosla S 1999 Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 140 5579-5586. (Pubitemid 30645345)
67. Grady D, Gebretsadik T, Kerlikowske K, Ernster V & Petitti D 1995 Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstetrics and Gynecology 85 304-313.
68. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF & Karin M 2004 IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 285-296.
69. Hachisuga T, Fukuda K, Nakamura S, Iwasaka T & Sugimori H 1997 Local immune response in endometrial carcinomas. British Journal of Obstetrics and Gynaecology 104 110-114. (Pubitemid 27019906)
70. Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R & Richmond A 2000 The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. Journal of Leukocyte Biology 67 53-62.
71. Hale GE, Hughes CL & Cline JM 2002 Endometrial cancer: hormonal factors, the perimenopausal "window of risk," and isoflavones. Journal of Clinical Endocrinology and Metabolism 87 3-15.
72. Hall JM & McDonnell DP 1999 The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 5566-5578.
73. Hanekamp EE, Gielen SC, Smid-Koopman E, Kuhne LC, de Ruiter PE, Chadha-Ajwani S, Brinkmann AO, Grootegoed JA, Burger CW, Huikeshoven FJ et al. 2003 Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clinical Cancer Research 9 4190-4199.
74. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E et al. 2007 Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. Journal of Clinical Oncology 25 4542-4549.
75. Hastings JM, Licence DR, Burton GJ, Charnock-Jones DS & Smith SK 2003 Soluble vascular endothelial growth factor receptor 1 inhibits edema and epithelial proliferation induced by 17β-estradiol in the mouse uterus. Endocrinology 144 326-334.
76. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K & Saiki I 2002 IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100 1728-1733. (Pubitemid 34925151)
77. He YY, Cai B, Yang YX, Liu XL & Wan XP 2009 Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Science 100 1051-1061.
78. Hendrickson M, Ross J, Eifel P, Martinez A & Kempson R 1982 Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. American Journal of Surgical Pathology 6 93-108. (Pubitemid 12108965)
79. Hornung D, Ryan IP, Chao VA, Vigne JL, Schriock ED & Taylor RN 1997 Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. Journal of Clinical Endocrinology and Metabolism 82 1621-1628. (Pubitemid 27200445)
80. Horwitz KB & McGuire WL 1978 Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. Journal of Biological Chemistry 253 2223-2228. (Pubitemid 8328205)
81. 2 production from early first trimester human decidual cells is inhibited by dexamethasone and progesterone. Prostaglandins 49 15-26.
82. Ito A, Imada K, Sato T, Kubo T, Matsushima K &Mori Y 1994 Suppression of interleukin 8 production by progesterone in rabbit uterine cervix. Biochemical Journal 301 183-186.
83. Ito K, Suzuki T, Akahira J, Moriya T, Kaneko C, Utsunomiya H, Yaegashi N, Okamura K & Sasano H 2002 Expression of androgen receptor and 5α-reductases in the human normal endometrium and its disorders. International Journal of Cancer 99 652-657.
84. Ito K, Utsunomiya H, Yaegashi N & Sasano H 2007 Biological roles of estrogen and progesterone in human endometrial carcinoma - new developments in potential endocrine therapy for endometrial cancer. Endocrine Journal 54 667-679. (Pubitemid 351377743)
85. 2 induces proliferation of glandular epithelial cells of the human endometrium via extracellular regulated kinase 1/2-mediated pathway. Journal of Clinical Endocrinology and Metabolism 88 4481-4487.
86. Jabbour HN, Milne SA, Williams AR, Anderson RA & Boddy SC 2001 Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. British Journal of Cancer 85 1023-1031. (Pubitemid 33016005)
87. 2α synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology 146 4657-4664.
88. Jabbour HN, Kelly RW, Fraser HM & Critchley HO 2006 Endocrine regulation of menstruation. Endocrine Reviews 27 17-46.
89. Jacobs AL, Sehgal PB, Julian J & Carson DD 1992 Secretion and hormonal regulation of interleukin-6 production by mouse uterine stromal and polarized epithelial cells cultured in vitro. Endocrinology 131 1037-1046.
90. 2 regulates tumor angiogenesis in prostate cancer. Cancer Research 68 7750-7759.
91. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA & Rice LW 2001 Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 20 6965-6969. (Pubitemid 33052187)
92. Jones RL, Kelly RW& Critchley HO 1997 Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Human Reproduction 12 1300-1306.
93. Ju W & Kim SC 2007 Polymorphisms in CAG active allele length of the androgen receptor gene are not associated with increased risk of endometrial cancer. Cancer Genetics and Cytogenetics 172 178-179. (Pubitemid 46043578)
94. Kaitu'u-Lino TJ, Morison NB & Salamonsen LA 2007 Neutrophil depletion retards endometrial repair in a mouse model. Cell and Tissue Research 328 197-206.
95. Kalandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D & Trichopoulos D 1996 A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncology 53 354-359. (Pubitemid 26283775)
96. Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ Jr & Coukos G 2010 The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology 116 222-233.
97. Karageorgi S, Hankinson SE, Kraft P & De Vivo I 2010 Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. International Journal of Cancer 126 208-216.
98. Kashima H, Shiozawa T, Miyamoto T, Suzuki A, Uchikawa J, Kurai M & Konishi I 2009 Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocrine-Related Cancer 16 113-122.
99. Keane MP, Belperio JA, Xue YY, Burdick MD & Strieter RM 2004 Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. Journal of Immunology 172 2853-2860.
100. Kelly RW, Illingworth P, Baldie G, Leask R, Brouwer S & Calder AA 1994 Progesterone control of interleukin-8 production in endometrium and chorio-decidual cells underlines the role of the neutrophil in menstruation and parturition. Human Reproduction 9 253-258. (Pubitemid 24076746)
101. Kelly RW, Carr GG & Riley SC 1997 The inhibition of synthesis of a β-chemokine, monocyte chemotactic protein-1 (MCP-1) by progesterone. Biochemical and Biophysical Research Communications 239 557-561.
102. King AE, Collins F, Klonisch T, Sallenave JM, Critchley HO & Saunders PT 2009 An additive interaction between the NFκB and estrogen receptor signalling pathways in human endometrial epithelial cells. Human Reproduction 25 510-518.
103. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr & Marks JR 1992 Overexpression and mutation of p53 in endometrial carcinoma. Cancer Research 52 1622-1627.
104. Kondratiev S, Sabo E, Yakirevich E, Lavie O & Resnick MB 2004 Intratumoral CD8+T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clinical Cancer Research 10 4450-4456. (Pubitemid 38878888)
105. Lavergne E, Combadiere C, Iga M, Boissonnas A, Bonduelle O, Maho M, Debre P & Combadiere B 2004 Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. Journal of Immunology 173 3755-3762.
106. Lax SF, Kendall B, Tashiro H, Slebos RJ & Hedrick L 2000 The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 814-824.
107. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K & Ting JP 2000 IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. Journal of Immunology 164 2769-2775.
108. Lin EY, Nguyen AV, Russell RG & Pollard JW 2001 Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. Journal of Experimental Medicine 193 727-740.
109. Lin YJ, Lai MD, Lei HY & Wing LY 2006 Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 147 1278-1286.
110. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L & Pienta KJ 2007 Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research 67 9417-9424.
111. Lovely LP, Appa Rao KBC, Gui Y & Lessey BA 2000 Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). Journal of Steroid Biochemistry and Molecular Biology 74 235-241.
112. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM & O'Malley BW 1995 Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes and Development 9 2266-2278.
113. Maehama T & Dixon JE 1998 The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Journal of Biological Chemistry 273 13375-13378.
114. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P & Bonecchi R 2009 The chemokine system in cancer biology and therapy. Cytokine and Growth Factor Reviews 21 27-39.
115. Martucci C & Fishman J 1977 Direction of estradiol metabolism as a control of its hormonal action-uterotrophic activity of estradiol metabolites. Endocrinology 101 1709-1715.
116. Marwood M, Visser K, Salamonsen LA & Dimitriadis E 2009 Interleukin-11 and leukemia inhibitory factor regulate the adhesion of endometrial epithelial cells: implications in fertility regulation. Endocrinology 150 2915-2923.
117. McDonald SE, Henderson TA, Gomez-Sanchez CE, Critchley HO & Mason JI 2006 11β-Hydroxysteroid dehydrogenases in human endometrium. Molecular and Cellular Endocrinology 248 72-78.
118. McGrath M, Lee IM, Hankinson SE, Kraft P, Hunter DJ, Buring J & De Vivo I 2006 Androgen receptor polymorphisms and endometrial cancer risk. International Journal of Cancer 118 1261-1268. (Pubitemid 43185615)
119. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL & Fishman J 1986 Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. New England Journal of Medicine 315 1305-1309.
120. Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A & Shroyer KR 2007 B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecologic Oncology 106 119-127.
121. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M & Inoue M 2007 Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Science 98 652-658.
122. Modugno F, Ness RB, Chen C & Weiss NS 2005 Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiology, Biomarkers and Prevention 14 2840-2847.
123. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML & Sinicrope FA 1999 Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Research 59 4356-4362.
124. Moysich KB, Baker JA, Rodabaugh KJ & Villella JA 2005 Regular analgesic use and risk of endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention 14 2923-2928.
125. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ & Power CA 2000 International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews 52 145-176.
126. Nilsson BO 2007 Modulation of the inflammatory response by estrogens with focus on the endothelium and its interactions with leukocytes. Inflammation Research 56 269-273.
127. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M et al. 1999 Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. Journal of Experimental Medicine 190 617-627.
128. Oh JH, Kim JH, Ahn HJ, Yoon JH, Yoo SC, Choi DS, Lee IS, Ryu HS & Min CK 2009 Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor κB. Gynecologic Oncology 114 509-515.
129. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G & Inoue M 2004 Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Research 24 3335-3342. (Pubitemid 39390949)
130. Ohno Y, Ohno S, Suzuki N, Kamei T, Inagawa H, Soma G & Inoue M 2005 Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. International Journal of Cancer 114 696-701. (Pubitemid 40344430)
131. Ohno S, Ohno Y, Nakada H, Suzuki N, Soma G & Inoue M 2006 Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis. Anticancer Research 26 4047-4053. (Pubitemid 46031550)
132. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277 1508-1510. (Pubitemid 27449239)
133. Pakrasi PL & Tiwari A 2007 Evidence of increased endometrial vascular permeability at the time of implantation in the short-nosed fruit bat, Cyanopterus sphinx. Animal Reproduction Science 101 179-185. (Pubitemid 46962253)
134. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J & Matias-Guiu X 2004 Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. Journal of Pathology 204 569-577. (Pubitemid 39585956)
135. Palucka K, Ueno H, Zurawski G, Fay J & Banchereau J 2010 Building on dendritic cell subsets to improve cancer vaccines. Current Opinion in Immunology 22 258-263.
136. Pole JC, Gold LI, Orton T, Huby R & Carmichael PL 2005 Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen. Toxicology 206 91-109. (Pubitemid 39601046)
137. Pomerantz JL & Baltimore D 2002 Two pathways to NF-κB. Molecular Cell 10 693-695.
138. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, Egashira K & Mukaida N 2009 Blockade of a chemokine, CCL2, reduces chronic colitis - associated carcinogenesis in mice. Cancer Research 69 7884-7892.
139. Purohit A & Reed MJ 2002 Regulation of estrogen synthesis in postmenopausal women. Steroids 67 979-983. (Pubitemid 35175465)
140. Purohit A, Singh A, Ghilchik MW & Reed MJ 1999 Inhibition of tumor necrosis factor α-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochemical and Biophysical Research Communications 261 214-217. (Pubitemid 29371643)
141. Reeves GK, Pirie K, Beral V, Green J, Spencer E & Bull D 2007 Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335 1134.
142. Rieck G & Fiander A 2006 The effect of lifestyle factors on gynaecological cancer. Best Practice & Research. Clinical Obstetrics & Gynaecology 20 227-251.
143. Rowe AJ, Wulff C & Fraser HM 2003 Localization of mRNA for vascular endothelial growth factor (VEGF), angiopoietins and their receptors during the
144. Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A et al. 2009 Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clinical Cancer Research 15 4299-4311.
145. Sahlin L, Norstedt G & Eriksson H 1994 Androgen regulation of the insulin-like growth factor-I and the estrogen receptor in rat uterus and liver. Journal of Steroid Biochemistry and Molecular Biology 51 57-66.
146. Salama SA, Kamel MW, Diaz-Arrastia CR, Xu X, Veenstra TD, Salih S, Botting SK & Kumar R 2009 Effect of tumor necrosis factor-α on estrogen metabolism and endometrial cells: potential physiological and pathological relevance. Journal of Clinical Endocrinology and Metabolism 94 285-293.
147. Salamonsen LA 2003 Tissue injury and repair in the female human reproductive tract. Reproduction 125 301-311.
148. Sales KJ, Grant V, Cook IH, Maldonado-Perez D, Anderson RA, Williams AR & Jabbour HN 2010 Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. American Journal of Pathology 176 435-445.
149. Sales KJ, Maudsley S & Jabbour HN 2004a Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3′,5′-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Molecular Endocrinology 18 1533-1545.
150. 2α receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. Journal of Clinical Endocrinology and Metabolism 89 986-993.
151. Sales KJ, List T, Boddy SC, Williams AR, Anderson RA, Naor Z & Jabbour HN 2005 A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Research 65 7707-7716.
152. Sales KJ, Boddy SC, Williams AR, Anderson RA & Jabbour HN 2007 F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 148 3635-3644.
153. Sales KJ, Boddy SC & Jabbour HN 2008a F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene 27 2466-2477.
154. 2α activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Molecular and Cellular Endocrinology 285 51-61.
155. Salvesen HB & Akslen LA 1999 Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. International Journal of Cancer 84 538-543.
156. Sandhu JS 2008 Prostate cancer and chronic prostatitis. Current Urology Reports 9 328-332.
157. Sauve K, Lepage J, Sanchez M, Heveker N & Tremblay A 2009 Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Research 69 5793-5800.
158. Scapini P, Morini M, Tecchio C, Minghelli S, Di Carlo E, Tanghetti E, Albini A, Lowell C, Berton G, Noonan DM et al. 2004 CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. Journal of Immunology 172 5034-5040.
159. Schultz G, Rotatori DS & Clark W 1991 EGF and TGF-α in wound healing and repair. Journal of Cellular Biochemistry 45 346-352.
160. Schutyser E, Struyf S & Van Damme J 2003 The CC chemokine CCL20 and its receptor CCR6. Cytokine & Growth Factor Reviews 14 409-426.
161. Seo KH, Lee HS, Jung B, Ko HM, Choi JH, Park SJ, Choi IH, Lee HK & Im SY 2004 Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB activation. Cancer Research 64 6482-6488. (Pubitemid 39297904)
162. Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K & Chiang N 2000 Anti-microinflammatory lipid signals generated from dietaryN-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. Journal of Physiology and Pharmacology 51 643-654. (Pubitemid 32049518)
163. Serhan CN, Chiang N & Van Dyke TE 2008 Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews. Immunology 8 349-361. (Pubitemid 351595216)
164. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R & Singh RK 2009a Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clinical Cancer Research 15 2380-2386.
165. Singh S, Varney M & Singh RK 2009b Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Research 69 411-415.
166. Slater M, Cooper M & Murphy CR 2006 Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochemica 108 13-18.
167. Smyth MJ, Crowe NY & Godfrey DI 2001 NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. International Immunology 13 459-463.
168. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M & Sato A 2008 Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecologic Oncology 109 122-128.
169. Sparmann A & Bar-Sagi D 2004 Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 447-458. (Pubitemid 39469981)
170. Srivastava K, Dasgupta PK, Srivastava AK & Murthy PS 1989 Role of plasminogen activators and leukocytes in IUD-induced inflammation: effect of some anti-inflammatory agents. Advances in Contraception 5 173-178. (Pubitemid 20083565)
171. St-Germain ME, Gagnon V, Parent S & Asselin E 2004 Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway. Molecular Cancer 3 7.
172. Straub RH 2007 The complex role of estrogens in inflammation. Endocrine Reviews 28 521-574.
173. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D et al. 1995 The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Journal of Biological Chemistry 270 27348-27357.
174. Suzuki H, Iwasaki E & Hibi T 2009 Helicobacter pylori and gastric cancer. Gastric Cancer 12 79-87.
175. Tabibzadeh S, Kong QF, Babaknia A & May LT 1995 Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Human Reproduction 10 2793-2799.
176. 2 and nuclear factor-κB. Journal of Biological Chemistry 277 26208-26216.
177. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M & Terao T 2002 Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Human Pathology 33 1105-1113.
178. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R & Ellenson LH 1997 Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research 57 3935-3940.
179. Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M & Hosokawa M 2003 Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. American Journal of Pathology 163 2221-2232. (Pubitemid 37466467)
180. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN & Dey SK 2000 Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2 483-490. (Pubitemid 32098682)
181. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M & DuBois RN 1998 Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 705-716. (Pubitemid 28257578)
182. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A & Kikkawa F 2007 Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction. Clinical & Experimental Metastasis 24 423-429. (Pubitemid 47367684)
183. Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K et al. 2004 PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood 104 3198-3204.
184. Vani S, Critchley HO, Fraser IS & Hickey M 2008 Endometrial expression of steroid receptors in postmenopausal hormone replacement therapy users: relationship to bleeding patterns. Journal of Family Planning and Reproductive Health Care 34 27-34.
185. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C & Naldini L 2007 Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109 5276-5285.
186. de Visser KE, Eichten A & Coussens LM 2006 Paradoxical roles of the immune system during cancer development. Nature Reviews. Cancer 6 24-37. (Pubitemid 43053650)
187. Viswanathan AN, Feskanich D, Schernhammer ES & Hankinson SE 2008 Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Research 68 2507-2513.
188. 2α-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Research 69 5726-5733.
189. Wang B, Hendricks DT, Wamunyokoli F & Parker MI 2006a A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Research 66 3071-3077.
190. Wang L, Zheng W, Zhang S, Chen X & Hornung D 2006b Expression of monocyte chemotactic protein-1 in human endometrial cancer cells and the effect of treatment with tamoxifen or buserelin. Journal of International Medical Research 34 284-290. (Pubitemid 44057271)
191. Wang L, Liu Q, Sun Q, Zhang C, Chen T & Cao X 2008 TLR4 signaling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20. Biochemical and Biophysical Research Communications 366 852-856.
192. Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW et al. 2007 Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 26 1971-1982.
193. Yamamoto M, Kikuchi H, Ohta M, Kawabata T, Hiramatsu Y, Kondo K, Baba M, Kamiya K, Tanaka T, Kitagawa M et al. 2008 TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Research 68 9754-9762.
194. Yamazawa K, Seki K, Matsui H & Sekiya S 2001 Significance of perivascular lymphocytic infiltrates in endometrial carcinoma. Cancer 91 1777-1784. (Pubitemid 32377964)
195. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J & Yan Q 2007 Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathology, Research and Practice 203 499-505. (Pubitemid 47065354)
196. Yang HP, Garcia-Closas M, Lacey JV Jr, Brinton LA, Lissowska J, Peplonska B, Chanock S & Gaudet MM 2009 Genetic variation in the androgen receptor gene and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention 18 585-589.
197. Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF & Wang SM 2007 Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. International Journal of Cancer 121 1949-1957. (Pubitemid 47463157)
198. Ye RD 2001 Regulation of nuclear factor κB activation by G-protein-coupled receptors. Journal of Leukocyte Biology 70 839-848. (Pubitemid 33151122)
199. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L & Vitale M 2007 NK cells and cancer. Journal of Immunology 178 4011-4016.
200. Zhao D, Li XP, Gao M, Zhao C, Wang JL & Wei LH 2006 Stromal cell-derived factor 1α stimulates human endometrial carcinoma cell growth through the activation of both extracellular signal-regulated kinase 1/2 and Akt. Gynecologic Oncology 103 932-937. (Pubitemid 44821317)